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Abstract
Background: There is little existing knowledge about actual quality of drugs provided by different
providers in Nigeria and in many sub-Saharan African countries. Such information is important for
improving malaria treatment that will help in the development and implementation of actions
designed to improve the quality of treatment. The objective of the study was to determine the
quality of drugs used for the treatment of malaria in a broad spectrum of public and private
healthcare providers.
Methods: The study was undertaken in six towns (three urban and three rural) in Anambra state,
south-east Nigeria. Anti-malarials (225 samples), which included artesunate, dihydroartemisinin,
sulphadoxine-pyrimethamine (SP), quinine, and chloroquine, were either purchased or collected
from randomly selected providers. The quality of these drugs was assessed by laboratory analysis
of the dissolution profile using published pharmacopoeial monograms and measuring the amount
of active ingredient using high performance liquid chromatography (HPLC).
Findings: It was found that 60 (37%) of the anti-malarials tested did not meet the United States
Pharmacopoeia (USP) specifications for the amount of active ingredients, with the suspect drugs
either lacking the active ingredients or containing suboptimal quantities of the active ingredients.
Quinine (46%) and SP formulations (39%) were among drugs that did not satisfy the tolerance limits
published in USP monograms. A total of 78% of the suspect drugs were from private facilities,
mostly low-level providers, such as patent medicine dealers (vendors).
Conclusion: This study found that there was a high prevalence of poor quality drugs. The findings
provide areas for public intervention to improve the quality of malaria treatment services. There
should be enforced checks and regulation of drug supply management as well as stiffer penalties for
people stocking substandard and counterfeit drugs.
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Background
People seek treatment for malaria from public sector facil-
ities and a range of formal and informal private sector
facilities [1,2]. Around 60% of all malaria episodes in sub-
Saharan Africa (SSA) are initially treated by private pro-
viders, mainly through the purchase of drugs from shops
and drug peddlers [1]. The "informal private sector", such
as patent medicine dealers, is a main source of anti-malar-
ial drugs [3,4], but the quality of treatment that they pro-
vide is suspect [1]. However, these treatments are often
inconsistent with national treatment guidelines: they may
include counterfeit drugs, drugs of poor quality, as well as
incorrect dosing and irrational prescription practices [4].
A counterfeit formulation is one that is "deliberately and
fraudulently mislabelled with respect to identity and/or
source. Counterfeiting can apply to both branded and
generic products and counterfeits may include products
with the correct ingredients or with the wrong ingredients,
without active ingredients, with insufficient active ingre-
dient or with fake packaging" [5]
Drug quality in public and private outlets may be prob-
lematic. A previous study in Nigeria assessed the quality of
drugs from retail outlets and pharmacies, and attributed
problems to a lack of quality control in manufacture and
degradation during storage [6].
A major problem with the treatment of malaria is the high
level of treatment failures resulting in the large part from
the high prevalence of counterfeit drugs bought by the
patients [7-9]. Anti-malarials, are among the most widely
consumed drugs in tropical countries that have been par-
ticularly targeted by counterfeiters and of the 12 anti-
malarial drugs used in the world today, eight have been
counterfeited [7]. Published estimates of the global prev-
alence of counterfeit drugs range from 1% to 50% and
there is evidence of 206 cases of counterfeit anti-infectives
from 38 countries [8]. The widespread prevalence of
counterfeit anti-malarials is of great public health concern
[7,8]. Also, lack of knowledge of counterfeits and appro-
priate preventive measures, together with poor dissemina-
tion of information among health workers and the public,
make their detection difficult [8].
Although the official treatment policy has been changed
as per WHO recommendations to the use of artemisinin-
based combination therapy (ACT) as first-line treatment
for malaria in Nigeria, the reality on the ground is the con-
tinued production, deployment and use of monothera-
pies, such as chloroquine (CQ), sulphadoxine-
pyrimethamine (SP), quinine (QU), artesunate and dihy-
droartemisinin, in both public and private facilities, espe-
cially by patent medicine dealers (vendors) in Nigeria and
other African countries. Artemisinin monotherapy
remains common in Africa [9]. Researchers have evalu-
ated the quality of CQ, quinine, SP, amodiaquine and
proguanil formulations sold in the market in various parts
of Africa, including eastern part of Congo DR and Kenya
[10-12]. Good quality anti-malarial drugs are often mis-
used in treating malaria because of under-dosing and
poor adherence, which could lead to treatment failures
and development of drug resistance. The use of counter-
feit or substandard monotherapies further endangers
malaria chemotherapy.
There is paucity of information about the quality of anti-
malarials in many sub-Saharan African (SSA) countries,
such as Nigeria. Most of the evidence about quality of
anti-malarials has come from South-East Asia. However,
in a six-country study that highlighted the availability and
relative quality of anti-malarials in Africa's private sector,
found that over 35% (73/210) of tested samples were sub-
standard [9]. In Nigeria, 36% of sampled anti-infectives
contained quantities of active ingredients outside phar-
macopoeial limits [6,8]. Also, from a random sample of
5% (n = 581) of Nigerian pharmacies, 48% of anti-infec-
tives contained active ingredients outside pharmacopoieal
limits [6,8]. In some cases, the drugs may contain more of
the stated active ingredients, which could lead to adverse
events as was found in Nigeria where 94 of 160 (59%) of
anti-malarials tested contained 110% or more of the
stated active ingredients [8,13].
There is little existing knowledge about actual quality of
drugs provided by different providers in Nigeria and in
many SSA countries. A search of the medical literature
yielded only 43 primary published research reports con-
cerning counterfeit drugs in the world [8]. Some research-
ers found 21 peer-reviewed articles and three reports on
the quality of anti-malarial drugs in Africa [14]. Failing
products more often originated or were claimed to origi-
nate from poorer parts of the world with weaker regula-
tory systems [9]. The critical finding by some researchers
was that most anti-malarial drugs pass the basic tests for
pharmaceutical dosage forms such as the uniformity of
weight for tablets and the content test, but that in vitro
product dissolution is the main problem [12,14].
Over the past decade, the massive public health problem
of counterfeit and substandard drugs has become more
manifest, leading to serious clinical consequences to
patients, such as increased morbidity, mortality, and drug
resistance, which leads to spurious reporting of resistance
and toxicity and loss of confidence in healthcare systems
[8,15,16]. Other studies looking at a broader range of dis-
eases in Nigeria found widespread inappropriate drug use,
low quality of treatment, and ineffective regulation [17-
21].
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The information generated by this study will help design
policy measures to strengthen the treatment component
of the malaria control strategy. Such information is espe-
cially important for improving malaria treatment, espe-
cially in light of the change of first-line drug to ACT in the
country. The information will also lead to the develop-
ment and implementation of targeted actions designed to
remedy problems found with respect to quality of treat-
ment. These remedial actions could include improved
training of public and private sector providers, strength-
ened regulation, and consumer education.
Methods
Study area
Anambra State, Southeast Nigeria was chosen for the
study. South-east Nigeria is one of the most important
sources of anti-malarial drugs in Africa and the "bridge-
head" market in Onitsha, Anambra State is at the centre of
this trade. The state has a high malaria transmission rate
all year and the annual incidence rate is 10 to 35%. Six
sites were chosen for the study. These were the three larg-
est urban centres (Awka (state capital), Nnewi and Onit-
sha), from each of the three senatorial zones and one rural
local government area (LGA), randomly selected from
each senatorial zone (Njikoka, Aguata and Ogbaru).
Then, one community from each of the three rural LGAs:
Enugwu-Ukwu (Njikoka LGA), Ekwulobia (Aguata LGA)
and Okpoko (Ogbaru LGA) was selected using two-stage
sampling, by first stratifying the communities according
to whether they have a general hospital and then ran-
domly selecting the sites from those that have general hos-
pitals. Each site area has a full complement of providers
from hospitals to itinerant drug providers and herbalists.
Sampling and sample size
The sample size was determined by considerations of the
range of providers and feasibility and was selected from a
broader study of nature of malaria treatment provision. In
the broader study, 50 providers (public and private) in
each urban and 25 in each rural area were selected, which
gave a total of 225 providers. The quality of drugs was
assessed through the purchase of anti-malarial drugs from
a random sample of 20% of the 225 selected providers.
They were spread out across the different levels of provid-
ers, but all existing public providers in each study area
were included in the study, because there were not many
of them. The sampling frame was providers using ortho-
dox drugs to treat patients and they included all levels of
care in public facilities and private providers. Orthodox
drugs refer drugs derived from biomedical science and
include tablets, syrups, suspensions and injections (in
contrast to herbs and homeopathic drugs). The providers
were divided into low-level providers and high/medium
level providers. The low-level providers included patent
medicine dealers, mixed goods shops and maternity
homes. The medium/high level providers included public
hospitals, private hospitals, pharmacy shops and primary
healthcare centres. Pharmacy shops are legal drug outlets
with an in-house pharmacist, whilst patent medicine deal-
ers are also legal drug outlets without an in-house phar-
macist.
Collection/purchase of drugs
The drugs were purchased from both low level and high/
medium level providers. The major drugs that are used in
the co-packaging of ACT, as well as the most common
anti-malarial were purchased. All drugs were purchased in
tablet form and the number of each tablet purchased was
determined by the type of anti-malarial and the recom-
mended single dose for treatment of malaria. The drugs
were artesunate, dihydroartesinin, SP, QU and CQ tablets.
The drugs were purchased in the following quantities:
artesunate – 12 tablets, dihydroartesinin – eight tablets,
SP – three tablets, quinine – 10 tablets, and CQ – 10 tab-
lets. Researchers posed as clients to buy the drugs from
pharmacy shops and patent medicine dealers (PMDs) or
vendors provided such drugs that had shelf lives of more
than two years. However, in the case of hospitals and a
few pharmacy shops, the researchers explained the pur-
pose of the study and requested that the providers sell the
anti-malarials to them, which all of them did. In some
cases, the hospitals donated the samples. Drugs of differ-
ent lot and batch numbers were bought/collected and the
samples for testing were randomly selected from those.
The drugs that were in packets were left in their packets,
but those that were bought in packs were safely stored in
medicine containers at room temperature (28°C to
32°C). Hence, efforts were made to ensure that the drugs
were not degraded by inadequate storage conditions,
which would have confounded the findings. The drugs
were stored for 4.5 months before the analysis. None of
the analysed drugs had expired.
Drug quality by dissolution analyses
The quality of the formulations of SP, quinine and CQ
was determined using the in vitro dissolution testing pro-
tocols using the detailed monograms outlined in the
United States Pharmacopeia (USP) and measuring the
amount of active component using high performance liq-
uid chromatographic (HPLC) analysis [22]. HPLC analy-
sis was carried out at the London School of Hygiene and
Tropical Medicine. The test for content assesses the
amount of active ingredient measured in a formulation,
expressed as a percentage of the label claim; the test for
dissolution determines the amount of active ingredient
that this released and available for absorption [11]. Poor
manufacturing practices, poor storage of a product as well
as the use of incorrect excipients will lead to poor dissolu-
tion profiles and thus result in compromised bioavailabil-
ity. Dissolution testing for pharmaceutical products in
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tablet and capsule form is required by the US Food and
Drug Administration (FDA) and increasingly used outside
the USA to report on the quality of drug.
Dissolution analyses
Tablet dissolution was performed in the Pharma Test PT
017 dissolution apparatus using 6 tablets of each product.
Dissolution of all antifolate antimalarial products was car-
ried out using 1 litre of 0.01 M pH 6.8 phosphate buffer
solution (sodium hydroxide and potassium dihydrogen
orthophosphate, Fisher Scientific) and heated to a tem-
perature of 37°C, with a rotor speed of 75 rpm. Dissolu-
tion was carried out for 40 minutes and 500 μl samples
were taken at ten-minute intervals during this time. Of
this 500 μl sample 200 μl was transferred into a high per-
formance liquid chromatography (HPLC) reaction vial
and diluted 1:1 with 200 μl 0.05 M pH 6.8 phosphate
buffer solution and transferred into the HPLC machine
for analysis. Dissolution of CQ was performed in 900 mls
of purified water and heated to a temperature of 37°C
with a rotor speed of 100 rpm for 60 minutes. At ten-
minute intervals, 500 μl samples were taken and from
each of these 200 μl was transferred for HPLC analysis
after a 1:1 dilution with purified water. The tablets were
subjected to dissolution in 900 mls of 0.1 Molar HCl and
heated to a temperature of 37°C, with a rotor speed of
100 rpm. Dissolution was carried out for 1 hour with 500
μl samples taken at ten-minute intervals during this time.
From each 500 μl sample 200 μl was transferred into a
HPLC reaction vial and diluted 1:1 with 200 μl 0.5 M HCl
and subsequently transferred into the HPLC machine for
analysis.
Quantity of active ingredient
Drug quality was assessed by comparing the amount of
active ingredient in the eluents of each dissolution sample
against a known concentration of the standard for CQ,
QU, SUL and PYR after HPLC analysis (see chromatogram
in Figure 1 for the separation for each compound). Infor-
mation about the source, packaging or appearance of each
HPLC chromatogram showing the separation of mixture of standards of chloroquine (CQ), quinine (QU), sulphadoxine (SUL) and pyrimeth mine (PYR) all at 10 μg/ml; dihydroartemisinin (DHA) and artesunate (AS) at 4 mg/mlFigure 1
HPLC chromatogram showing the separation of mixture of standards of chloroquine (CQ), quinine (QU), sul-
phadoxine (SUL) and pyrimethamine (PYR) all at 10 μg/ml; dihydroartemisinin (DHA) and artesunate (AS) at 
4 mg/ml.
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product was not known by the investigators prior to anal-
yses of the tablets for quality.
After the dissolution and HPLC analyses the samples were
classified as good quality or substandard based on the
amount of active ingredient detected listed in Table 1,
below. Similarly in the absence of an official monograph
for the dissolution profile of artemisinin derivatives –
artesunate (AS) and dihydroartemisinin (DHA) – concen-
trations were measured directly by crushing the tablets
and adding 20 ml of methanol to obtain a 2.5 mg/ml
solution of AS or DHA per tablet. This solution was then
analysed on HPLC to confirm the amount measured. The
amount of active ingredient detected was determined
from a calibration curve plotted using reference standards
of each of the artemisinin derivatives (0–10 mgs/ml)
For SP, USP stipulates that 60% of each component must
be detected in the dissolution media (phosphate buffer
0.05 M; pH 6.8) at 30 minutes (37°C). For quinine an
amount of more than 75% must be detected in the disso-
lution media (0.1 N hydrochloric acid) at 45 minutes
(37°C), while for CQ, 75% of the active ingredient should
be detected in the dissolution media (water) at 45 min-
utes (37°C). Dissolution tests and percentage of active
ingredients of the drug samples were the major points for
data analysis. The final results (Table 1) were expressed as
whether or not the drugs failed to meet the tolerance lim-
its stated in the monograms of USP and the proportion of
active ingredients that each sample contained. As reported
by Bate et al, forensic examination of trademarks or prod-
uct designs were carried out to differentiate between prod-
ucts that were merely substandard and those which were
deliberately counterfeited [8].
Results
General characteristics of the providers
The basic training and service information of low level
healthcare providers and medium/high level providers
showed that amongst the low level providers, those in
maternity homes had the highest average number of years
of formal training for the work that they do. Similarly, it
was providers in 'other healthcare facilities' that had the
highest number of years of training for the work that they
do, whilst providers in private hospitals, the general hos-
pitals and 'others' had the highest level of education for
medium/high level providers. All the medium/high level
providers were licensed for the work that they do, with the
exception of one provider from a Primary Healthcare
(PHC) centre. Conversely, 121 (94.5%) of the low level
providers were licensed, however the level of education
for most patent medicine dealers, specifically for the med-
icine business, was very low. Overall, there were 128 low-
level providers and 97 medium/high level providers.
Drugs stocked and used by providers to treat malaria
In the survey interview conducted with all 225 selected
providers, artesunate monotherapy, chloroquine tablets,
chloroquine injection, antibiotics, SP, quinine, ACT and
other drugs were stated as the drugs that 30.9%, 70%,
54.6%, 24.7%, 56.7%, 23.7%, 11.3%, 38.1% medium/
high level providers most commonly used to treat
malaria. The use of artesunate monotherapy was mostly
in public (81.8%) and private hospitals (100%) and phar-
macies (63.6%) respectively. Also, CQ tablets (90.6%)
and SP formulations (84.4%) were the most common
drugs used by low-level providers to treat malaria. Only
24.2% and 0.8% of low-level providers used artesunate
monotherapy and ACT, respectively to treat malaria. The
few instances of known use of ACT by medium/high level
providers were in general hospitals and pharmacy shops.
At the time of the interview the medium/high level pro-
viders had in stock artesunate monotherapy (29.9%), CQ
tablets (61.9%), CQ injection (57.7%), antibiotics
(20.6%), SP (45.4%), quinine (22.1%) and ACTs
(14.4%). Most of the formulations for artesunate mono-
therapy and ACT were stocked by the public hospitals and
pharmacy shops. Conversely, at the time of interview, just
27 (21.1%) and two (1.6%) of low level providers had in
stock artesunate monotherapy and ACT and 88.3% of
them stocked both CQ and SP tablets at that time.
Quality of different anti-malarials in the study area
Table 2 shows that 60 (37%) out of the 225 anti-malarials
did not meet the tolerance limits set by USP for the
amount of active ingredient when tested for the quality of
the formulations. The drugs that did not meet the toler-
ance limits set by USP either did not contain the active
ingredients or contained suboptimal quantities of the
Table 1: Classification for content analysis by HPLC for antimalarial drugs
Drug Good Quality
Chloroquine > 0.208 mg/ml at 45 minutes (if CQ = 250 mg dose)
Quinine > 0.25 mg/ml at 45 minutes (if QU = 300 mg or 0.08 mg/ml if it is 100 mg)
Sulfadoxine > 0.3 mg/ml at 30 minutes
Pyrimethamine > 0.015 mg/ml at 30 minutes
ARTs > 95% of stated concentration
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stated active ingredient/s. Most of the drugs that did not
meet the tolerance limits set by USP were found with
respect to quinine (46%) and SP preparations (39%).
Table 3 shows the sources of the drugs that did not meet
the tolerance limits set by USP by type of provider. A total
of 78% of the drugs that did not meet the tolerance limits
set by USP were found in private facilities, mostly in pat-
ent medicine stores. Similarly, 60% of the drugs that did
not meet the tolerance limits set by USP were found in
low-level providers, mostly in patent medicine stores.
Seven of the quinine tablets contained only chloroquine.
One sample of the total of four samples of dihydroartem-
isinin collected, was a counterfeit and one tablet of CQ
contained half the amount of active ingredient, with one
CQ sample actually containing nothing which by defini-
tion implies it is a counterfeit. Chi-square analysis shows
that the difference between the urban and rural areas in
drugs that did not meet the tolerance limits set by USP was
statistically significant (Chi-square = 51.24, df = 12, p <
.0001). Table 4 shows that the quality of drugs, especially
SP and quinine were quite bad in the rural areas, when
compared with the situation in the urban areas.
Discussion
There was a high prevalence of many failing anti-malarial
drugs in the study area, which is at the heart of pharma-
ceutical trade in West Africa. Given that the drugs tested
where the drugs also mentioned by the providers that
were interviewed as the most commonly used drugs for
malaria treatment, it leads to many cases of apparent
malaria treatment failures, and misdiagnosis of such to be
enteric fever as is common in Nigeria. All these lead to
economic loss and death as well as increasing cases of
drug resistance. It was alarming that many of the drugs
that did not meet the tolerance limits set by USP were
from licensed providers and that the current prevalence
rate is similar (36%) as reported in an earlier study [6].
The results are also similar to the findings in the eastern
region of Congo DR, where high prevalence of substand-
ard CQ, QU and SP were found [10], and similarly in
Kenya, where there was high prevalence of substandard SP
and amodiaquine [11]. In Cameroon, which shares a bor-
der with Nigeria, it was found that of the tested CQ
(38%), QU (74%) and antifolates (12%) had either no
active ingredient, an insufficient active ingredient, the
Table 2: Showing the quality of different anti-malarials in different study communities
Dihydroartemesinin
N = 4
n (%)
Quinine
N = 28
n (%)
Sulphadoxine-Pyrimethamine (SP)
N = 113
n (%)
Chloroquine
N = 56
n (%)
Artesunate
N = 24
n (%)
Total
N = 225
n (%)
Pass* 3 (75) 15 (54) 69 (61) 54 (96) 24 (100) 165 (73)
Fail* 1 (25) 13 (46) 44 (39) 2 (4) 0 (0) 60 (37)
Total 4 (100) 28 (100) 113(100) 56 (100) 24 (100) 225 (100)
Failures
Public 0 (0) 2 (15) 9 (21) 2 (100) 0 (0) 13 (22)
Private 1 (100) 11 (85) 35 (79) 0 (0) 0 (0) 47 (78)
Total 1 (100) 13 (100) 44 (100) 2 (100) 0 (0) 60 (100)
Failures
Low level 0 (0) 10 (77) 25 (57) 1 (50) 0 (0) 36 (60)
High/med 1 (100) 3 (23) 19 (43) 1 (50) 0 (0) 24 (40)
Total 1 (100) 13 (100) 44 (100) 2 (100) 0 (0) 60 (100)
Note: A failure in the context of the study implies that the tablets did not meet the USP tolerance limits for quality test for active ingredient 
released during the dissolution test.
Table 3: Showing the sources of drugs that failed quality tests by type of provider
Dihydroartemesinin
N = 1
n (%)
Quinine
N = 13
n (%)
(SP)
N = 44
n (%)
Chloroquine
N = 2
n (%)
Patent medicine dealers 0 7 (53.9%) 23 (52.5%) 0
Pharmacy shops 0 3 (23.1%) 13 (29.6%) 0
Private hospital 1 (100) 1 (7.7%) 0 (0) 0
Public Hospital 0 0 (0) 4 (9.1%) 2 (100%)
Primary healthcare centers 0 2 (15.4%) 4 (9.1%) 0
Total 1 (100) 13 (100) 44 (100) 2 (100%)
Χ2 for urban rural differences in failed drugs = 51.24, df = 12, p < .0001.
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wrong ingredient, or unknown ingredient(s) [23]. These
results are similar to those reported from the study from
SE Asia, where an increasing high proportion of anti-
malarial drugs bought in pharmacies and shops are coun-
terfeit [24]. Poor quality artemisinin monotherapies such
as dihydroartemisinin have also been reported from for-
mulations tested in Kenya [14].
Unexpectantly cheap drugs such as SP formulations and
quinine, and to a lesser extent CQ, which are most com-
monly used by the very poor, were counterfeit. Similarly,
it was found that 33% of CQ batches were under dosed in
eastern region of Congo DR [10]. Hence, as argued by
some researchers, the previous suggestions that relatively
inexpensive drugs, such as CQ are not commonly faked is
not borne out by data [8]. The results compare well with
the those from another study where it was found that var-
ious substandard therapies and clinically inappropriate
mono-therapies remain widely used, with between a quar-
ter half of the products failing basic quality tests [9]. Spe-
cifically 33% of artemesinin monotherapies failed thin-
layer chromatography tests [9]. The case of high failure
rate of quinine is of grave concern because physicians in
Nigeria usually rely on this drug for cases of suspected
treatment failures to other drugs and in emergencies. Also,
the high level of SP formulations that did not meet the tol-
erance limits set by USP portends danger for pregnant
women, as this drug is the mainstay of intermittent-pre-
ventive treatment of malaria in pregnancy (IPTp).
The motive for such sustained high prevalence could be
the inordinate objective of high profit making by unscru-
pulous businessmen aided by pharmaceutical manufac-
turers. It has been estimated that the counterfeit medicine
market is worth some US$35–44 billion per year [8].
However, it was stated that numerous factors encourage
the counterfeiting of drugs apart from criminal greed [8].
The relatively high cost of genuine medicines, together
with their desirability and low availability, give the coun-
terfeiters an economic incentive, facilitated by lack of leg-
islation and enforcement and light penalties [8].
The pattern of low quality of drugs that was found in this
study has equity implications for appropriate treatment of
malaria in Anambra state and even Nigeria. This is
because the private and low-level providers, where the
drugs that did not meet the tolerance limits set by USP
were available are usually predominantly used more by
the poorer/poorest socio-economic status (SES) groups
[1]. In Tanzania, there was availability of low quality SP
and amodiaquine tablets in wholesale pharmacies [15].
Similarly in Cambodia, it was found that out of 133 drug
vendors, 71% and 60% had counterfeit artesunate and
mefloquine respectively [8,25]. The low level providers
with the drugs that did not meet the tolerance limits set by
USP are also usually the places where quality of malaria
treatment is usually the lowest [1]. These findings mean
that the poorer and most poor SES received the lowest
quality of treatment from all ramifications. As such,
urgent interventions should be developed and imple-
mented to remedy this inequity, as counterfeit drugs par-
ticularly affect the most disadvantaged people in resource
poor countries [8].
Improved drug quality for treatment of malaria will
require concerted educational intervention for providers
and consumers to enhance procurement of good quality
drugs and, improved regulation of the drugs. This is espe-
cially pertinent because there was greater prevalence of
poor quality drugs in the rural areas where there is lack of
knowledge and ignorance by both providers and consum-
ers about quality of healthcare is rife, and they also lack
awareness of the consequences of counterfeit drugs. In
Laos, it was found that 63% of drug sellers and 80–96%
of consumers were not aware of the existence of poor
quality drugs [8,26]. The finding that some drugs con-
tained the wrong stated active ingredient or contained
nothing is quite worrying in the study area used for this
study, where Plasmodium falciparum causes more than
90% of the malaria. This can lead to increased morbidity
and mortality if counterfeit drugs are used for treatment.
ACT is expensive and the current policy to use such com-
binations as first-line drugs implies an urgent need to
Table 4: Rural urban differences in drug quality
SP Quinine CQ DHA AS
total Failed* total Failed* total Failed* total Failed* total Failed*
Urban areas 54 20 (37.0%) 16 7 (43.8%) 26 1 (3.9%) 4 1 (25%) 12 0 (0%)
Rural areas 59 26 (44.1%) 12 8 (66.7%) 30 1 (3.3%) 0 0 (0%) 12 0 (0%)
Grand total 113 46 (40.7%) 28 15 (53.6%) 56 2 (3.6%) 4 1 (25%) 24 0 (0%)
Note: Pass or fail implies that the tablets met or did not meet the USP tolerance limits for quality test
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decrease the spread of counterfeit drugs in the system,
otherwise people will be wasting sums of money buying
counterfeit ACT. The incidence of morbidity and mortal-
ity may also increase as well as resistance to these effective
drugs against malaria.
The recommended actions for improving the quality of
malaria treatment may include refresher and fresh train-
ing and capacity building for all providers but with special
and priority emphasis on patent medicine dealers so as to
enhance their quality of drug acquisition. With the recent
introduction of ACT in Nigeria, many of the combina-
tions in the markets are not co-formulated but co-pack-
aged and many health providers either prescribe co-
packaged drugs or undertake the co-packaging themselves
or prescribe two monotherapies with instructions on how
to consume them together. Hence, information about the
quality of drugs used in the co-packaging or co-prescrip-
tions as ACT is very useful for improving malaria case
management. Although advances in forensic chemical
analysis and simple field tests will enhance drug quality
monitoring, improved access to inexpensive genuine
medicines, support of drug regulatory authorities, greater
open reporting, vigorous law enforcement, and interna-
tional cooperation with determined political leadership
will be essential to counter this threat [8]. The State Min-
istry of Health (SMOH) should collaborate with the
National Agency for Food, Drug Administration and Con-
trol (NAFDAC) to tackle high incidence of counterfeit
drugs in the State. It seems that as the war against sub-
standard and counterfeit drugs is being waged in the
urban areas by the relevant authorities, the problem con-
tinues relatively unabated in the rural areas and amongst
low level providers. The Department of Pharmacy in the
SMOH in collaboration with the health departments of
the local government areas should develop and imple-
ment drug quality assurance strategy in the state, which
should also lay emphasis on rural areas, in addition to the
urban areas.
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